UNSPSC 51321705: Phosphatidylcholine

This classification denotes an anti-lipidemic agent with the molecular formula C10H20NO8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1109Z9J4N, chemically known as [(2R)-2,3-diformyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate, but generally known as phosphatidylcholine, which bears US NIH Compound Identifier 45266626. SMILES: C[N+](C)(C)CCOP(=O)([O-])OCC(COC=O)OC=O.

UNSPSC 51321705 Phosphatidylcholine is a Commodity code that captures advanced life support and emergency medications procured by state and local health agencies, fire departments, and pharmacy benefit programs. State and local governments buy this code as part of critical-care medication supply chains, emergency medical services inventories, and pharmacy benefit program sourcing — not as a standalone chemical product. The issuing bodies range from municipal fire departments (Tampa Fire Rescue) to state health agencies (Texas Health and Human Services Commission) to cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance). Work under the code includes sealed competitive bidding for specific medication line items with firm pricing and managed expiration timelines, Request for Information market intelligence gathering on direct-to-manufacturer prescription programs, and multi-state cooperative RFPs establishing master supply agreements through authorized wholesale channels.

Recent activity clusters in Florida and Minnesota, with secondary activity in Texas. The City of Tampa issued an IFB (Bid No. 26-P-00188) due April 8, 2026, for Advanced Life Support Medications (370 units Labetalol HCI, 1,810 units Epinephrine, 330 units Adenosine, 1,020 units Diltiazem) with a one-year term renewable for two additional years, an estimated contract value of $40,000, and a 5 percent SLBE bid discount capped at $10,000. The Texas Health and Human Services Commission released RFI No. HHS0017013 (response deadline April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription contracting outside traditional PBM and GPO channels. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026, and a weighted evaluation emphasizing price competitiveness (75 percent). All three opportunities require FDA compliance, cGMP certification, and drug supply chain security documentation.